Deutsche Bank AG Has $4.43 Million Stock Position in TG Therapeutics, Inc. (NASDAQ:TGTX)

Deutsche Bank AG lifted its stake in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 40.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 147,020 shares of the biopharmaceutical company's stock after acquiring an additional 42,272 shares during the quarter. Deutsche Bank AG owned approximately 0.09% of TG Therapeutics worth $4,425,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the business. Cornerstone Select Advisors LLC acquired a new position in TG Therapeutics during the fourth quarter worth approximately $1,904,000. Brevan Howard Capital Management LP acquired a new position in TG Therapeutics during the fourth quarter worth approximately $453,000. Balyasny Asset Management L.P. acquired a new position in TG Therapeutics during the fourth quarter worth approximately $274,000. Baird Financial Group Inc. increased its position in TG Therapeutics by 7.6% during the fourth quarter. Baird Financial Group Inc. now owns 56,129 shares of the biopharmaceutical company's stock worth $1,689,000 after buying an additional 3,947 shares during the last quarter. Finally, Freestone Grove Partners LP acquired a new position in TG Therapeutics during the fourth quarter worth approximately $224,000. Institutional investors and hedge funds own 58.58% of the company's stock.

TG Therapeutics Trading Up 1.8%

Shares of NASDAQ:TGTX opened at $34.98 on Tuesday. TG Therapeutics, Inc. has a 12-month low of $15.16 and a 12-month high of $46.48. The stock has a market cap of $5.55 billion, a PE ratio of -349.77 and a beta of 2.21. The business has a 50 day moving average of $38.54 and a 200-day moving average of $34.08. The company has a quick ratio of 3.91, a current ratio of 4.59 and a debt-to-equity ratio of 1.27.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The biopharmaceutical company reported $0.03 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.19 by ($0.16). TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. The firm had revenue of $120.86 million for the quarter, compared to the consensus estimate of $117.07 million. During the same quarter in the prior year, the firm earned ($0.07) EPS. The company's revenue was up 90.4% on a year-over-year basis. As a group, equities research analysts forecast that TG Therapeutics, Inc. will post 0.08 earnings per share for the current year.

Analyst Upgrades and Downgrades

TGTX has been the topic of a number of recent analyst reports. HC Wainwright reissued a "buy" rating and set a $55.00 price target on shares of TG Therapeutics in a research report on Tuesday, March 4th. StockNews.com raised TG Therapeutics from a "sell" rating to a "hold" rating in a research report on Tuesday, March 4th. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $40.80.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.

Want to see what other hedge funds are holding TGTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.